H.R.878 - Right to Try Act of 2017115th Congress (2017-2018) |
|Sponsor:||Rep. Biggs, Andy [R-AZ-5] (Introduced 02/06/2017)|
|Committees:||House - Energy and Commerce; Judiciary|
|Latest Action:||03/02/2017 Referred to the Subcommittee on Crime, Terrorism, Homeland Security, and Investigations. (All Actions)|
This bill has the status Introduced
Here are the steps for Status of Legislation:
- Passed House
- Passed Senate
- To President
- Became Law
Summary: H.R.878 — 115th Congress (2017-2018)All Information (Except Text)
Introduced in House (02/06/2017)
Right to Try Act of 2017
This bill requires the federal government to allow unrestricted manufacturing, distribution, prescribing, and dispensing of experimental drugs, biological products, and medical devices that are: (1) intended to treat a patient who has been diagnosed with a terminal illness, and (2) authorized by state law. The federal government must allow unrestricted possession and use of such treatments by patients certified by a physician as having exhausted all other treatment options.
A manufacturer, distributor, prescriber, dispenser, possessor, or user of such a treatment has no liability regarding the treatment.
The outcome of manufacture, distribution, prescribing, dispensing, possession, or use of such a treatment may not be used by a federal agency to adversely impact review or approval of the treatment.
The treatment must: (1) have successfully completed a phase 1 (initial, small scale) clinical trial; (2) remain under investigation in a clinical trial approved by the Food and Drug Administration; and (3) not be approved, licensed, or cleared for sale under the Federal Food, Drug, or Cosmetic Act or the Public Health Service Act.